Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
7 hedge funds and large institutions have $12.4K invested in Syros Pharmaceuticals, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 38 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
19.51% less ownership
Funds ownership: 19.51% → 0% (-20%)
84% less funds holding
Funds holding: 44 → 7 (-37)
97% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 38
99% less capital invested
Capital invested by funds: $1.2M → $12.4K (-$1.19M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$13.6K |
| 2 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$10.4K |
| 3 |
FIA
FNY Investment Advisers
New York
|
+$1.85K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$695 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$632K |
| 2 |
BlackRock
New York
|
-$63.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$61.7K |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$57.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$45.1K |
SYRS Hedge Fund Activity: Q1 2025 in Review
7 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2025, worth a combined $12.4K — down 99% from $1.2M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of SYRS and 1 opened new positions — a net loss of 37 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Acadian Asset Management, adding an estimated $13.6K. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $632K sold.
- 7 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2025, down from 44 in Q4 2024.
- Funds reported $12.4K of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2025, down 99% quarter-over-quarter.
- 1 fund opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2025 and 38 closed out, a net change of -37 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2025 was Acadian Asset Management, an estimated $13.6K added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2025 was Bain Capital Life Sciences Investors, an estimated $632K sold.
Based on aggregated 13F filings for Q1 2025.